Gentherm Beats Q2 Estimates, Raises FY26 Outlook, Launches $400M Buyback
THRM sits 56% above its 52-week low of $27.
Summary
Gentherm delivered a strong Q2 beat with adjusted EPS of $0.75 versus the $0.56 consensus and revenue of $416.2M, up 11% year-over-year and well above the $382.9M estimate. Management raised full-year product revenue guidance to $1.55B-$1.65B, up from $1.5B-$1.6B, signaling confidence in accelerating growth across home, office, and medical markets. The board also authorized a new $400M stock buyback program, replacing the existing plan with $110M remaining, which underscores capital allocation priorities. Shares surged 12% to $40.43, approaching the 52-week high of $42.35. This follows the recent FDA clearance for the ThermAffyx system and the acquisition of Innovative Medical Equipment, reinforcing the healthcare expansion narrative. The pending Modine merger adds strategic complexity, but today's results highlight standalone momentum.
At the time of this announcement, THRM was trading at $42.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $27.00 to $42.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.